Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail (BusinessWire)

Ology Bioservices Awarded $37 Million for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail

UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced that the Department of Defense (DOD) has awarded the company with an agreement valued at $37 million. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.

“This award will allow Ology Bio to extend our rapid development and manufacturing capabilities by introducing the critical regulatory component,” said Peter H. Khoury, Ph.D., president and CEO of Ology Bio.

Learn more about Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail.
X